These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

317 related items for PubMed ID: 18941518

  • 1. Mycolactone diffuses from Mycobacterium ulcerans-infected tissues and targets mononuclear cells in peripheral blood and lymphoid organs.
    Hong H, Coutanceau E, Leclerc M, Caleechurn L, Leadlay PF, Demangel C.
    PLoS Negl Trop Dis; 2008; 2(10):e325. PubMed ID: 18941518
    [Abstract] [Full Text] [Related]

  • 2. Mycolactone diffuses into the peripheral blood of Buruli ulcer patients--implications for diagnosis and disease monitoring.
    Sarfo FS, Le Chevalier F, Aka N, Phillips RO, Amoako Y, Boneca IG, Lenormand P, Dosso M, Wansbrough-Jones M, Veyron-Churlet R, Guenin-Macé L, Demangel C.
    PLoS Negl Trop Dis; 2011 Jul; 5(7):e1237. PubMed ID: 21811642
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Selective suppression of dendritic cell functions by Mycobacterium ulcerans toxin mycolactone.
    Coutanceau E, Decalf J, Martino A, Babon A, Winter N, Cole ST, Albert ML, Demangel C.
    J Exp Med; 2007 Jun 11; 204(6):1395-403. PubMed ID: 17517970
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Mycolactone-mediated inhibition of tumor necrosis factor production by macrophages infected with Mycobacterium ulcerans has implications for the control of infection.
    Torrado E, Adusumilli S, Fraga AG, Small PL, Castro AG, Pedrosa J.
    Infect Immun; 2007 Aug 11; 75(8):3979-88. PubMed ID: 17517872
    [Abstract] [Full Text] [Related]

  • 8. Mycolactone suppresses T cell responsiveness by altering both early signaling and posttranslational events.
    Boulkroun S, Guenin-Macé L, Thoulouze MI, Monot M, Merckx A, Langsley G, Bismuth G, Di Bartolo V, Demangel C.
    J Immunol; 2010 Feb 01; 184(3):1436-44. PubMed ID: 20042571
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Immunosuppressive signature of cutaneous Mycobacterium ulcerans infection in the peripheral blood of patients with buruli ulcer disease.
    Phillips R, Sarfo FS, Guenin-Macé L, Decalf J, Wansbrough-Jones M, Albert ML, Demangel C.
    J Infect Dis; 2009 Dec 01; 200(11):1675-84. PubMed ID: 19863437
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Vaccination with the Surface Proteins MUL_2232 and MUL_3720 of Mycobacterium ulcerans Induces Antibodies but Fails to Provide Protection against Buruli Ulcer.
    Bolz M, Bénard A, Dreyer AM, Kerber S, Vettiger A, Oehlmann W, Singh M, Duthie MS, Pluschke G.
    PLoS Negl Trop Dis; 2016 Feb 01; 10(2):e0004431. PubMed ID: 26849213
    [Abstract] [Full Text] [Related]

  • 16. Buruli ulcer.
    Einarsdottir T, Huygen K.
    Hum Vaccin; 2011 Nov 01; 7(11):1198-203. PubMed ID: 22048117
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Chemistry of mycolactones, the causative toxins of Buruli ulcer.
    Kishi Y.
    Proc Natl Acad Sci U S A; 2011 Apr 26; 108(17):6703-8. PubMed ID: 21383136
    [Abstract] [Full Text] [Related]

  • 19. Induced Synthesis of Mycolactone Restores the Pathogenesis of Mycobacterium ulcerans In Vitro and In Vivo.
    Strong E, Hart B, Wang J, Orozco MG, Lee S.
    Front Immunol; 2022 Apr 26; 13():750643. PubMed ID: 35401531
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.